Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

To evaluate the efficacy of combining the dual endothelin receptor antagonist, bosentan, and the phosfodiesterase-5-inhibitor, sildenafil, in patients with Eisenmenger syndrome.
OriginalsprogEngelsk
TidsskriftEuropean Heart Journal
Vol/bind31
Udgave nummer9
Sider (fra-til)1124-31
Antal sider8
ISSN0195-668X
DOI
StatusUdgivet - 1 maj 2010

ID: 34080333